Company intelligence / Profile preview

BioCardia, Inc.

Sunnyvale, California, United Statesbiocardia.com ↗

Ownership: Public · BCDA
Development stage: Phase 3

Overview

BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its lead program, CardiAMP® autologous cell therapy for ischemic heart failure with reduced ejection fraction, has completed its last protocol-specified follow-up visit in a pivotal trial as of Q4 2024. Data analysis from the CardiAMP HF Trial was near completion as of March 2025 with results to be presented at a major cardiology conference. The company has ongoing regulatory engagement with both the FDA and Japan’s PMDA regarding potential registration based on these data[2].

Therapeutic areas: Cardiovascular
Modalities: Cellular therapeutics (autologous cell therapy)Cell-derived therapeutics
Industry: Biotech

Drug pipeline

6 assets

HeartReady

Preclinical

5 more assets in the full pipeline.

Request access →

Financials

Market cap: $16.4M
Total revenue: $0
Enterprise value: $12.5M

Beyond the preview

Go deeper on BioCardia, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCardia, Inc..

Explore the full profile